The marketing authorization for TEPEZZA in the European Union for thyroid eye disease (TED) represents a significant geographic expansion. This will require investment in building out commercial infrastructure, supply chain logistics, and marketing campaigns across Europe.
Filing excerpt
In June 2025, the European Commission granted marketing authorization approval of TEPEZZA for treatment of adults with moderate-to-severe thyroid eye disease (TED).
What this signalsFilings often name leadership changes, deals and spending plans.
Regions named
sec-10kmarketExpansionGet every 10-K signal for Amgen and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Amgen this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/39b472c5-607c-41d6-82ce-ed0f982976cf returns this record as JSON. POST /v1/companies/enrich returns every signal for amgen.com.
{
"signal_id": "39b472c5-607c-41d6-82ce-ed0f982976cf",
"signal_type": "sec-10k",
"signal_subtype": "marketExpansion",
"detected_at": "2026-02-17T06:28:58.463+00:00",
"company": {
"name": "Amgen",
"domain": "amgen.com"
},
"data": {
"detail": "The marketing authorization for TEPEZZA in the European Union for thyroid eye disease (TED) represents a significant geographic expansion. This will require investment in building out commercial infrastructure, supply chain logistics, and marketing campaigns across Europe.",
"metrics": {
"timeframe": "current_year"
},
"summary": "Amgen received European Commission approval for TEPEZZA in June 2025, expanding into the EU market",
"excerpts": "In June 2025, the European Commission granted marketing authorization approval of TEPEZZA for treatment of adults with moderate-to-severe thyroid eye disease (TED).",
"relevance": 0.8,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm",
"filing_date": "2026-02-13",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Scaling infrastructure needed",
"signal_category": "market",
"regions_mentioned": [
"Europe"
]
}
}
curl https://signals.autobound.ai/v1/signals/39b472c5-607c-41d6-82ce-ed0f982976cf \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"amgen.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.